Revelation Partners

Revelation Partners, LLC is a private equity and venture capital firm based in San Francisco, California, founded in 2012. The firm specializes in buyout, direct, and fund of fund investments, primarily focusing on late-stage companies within the healthcare sector. Its investment strategy emphasizes commercial enterprises with proven business models or innovative technologies that have clear clinical and regulatory pathways. Revelation Partners typically invests between $5 million and $30 million, with the capacity to engage in larger deals alongside limited partners. The firm concentrates on medical devices, biopharmaceuticals, healthcare information technology, and healthcare services, often seeking majority stakes in its investments. Additionally, it engages in secondary investments and offers liquidity solutions to existing investors looking to divest.

Mike Boggs

Director

Garrett Brown

Senior Associate

Doug Fisher

Partner

Keegan Hasson

Senior Associate

Fred Lee

Partner

Fred Lee

Partner

Courtney Munley

Associate

Andrew Olson

Partner, CFO and COO

Andrew Olson

Partner, CFO and COO

Rob Rein

Vice President

Liz Staley

Partner and CCO

Scott Halsted

Managing Partner

50 past transactions

Arbor Biotechnologies

Series C in 2025
Arbor Biotechnologies, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, operates as a bio-discovery company in the biotechnology sector. The company focuses on developing genomic tools that enhance human health and sustainability. Utilizing a combination of artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, Arbor's platform accelerates the discovery of proteins and facilitates human diagnostic development. The technology aggregates genomic sequence data through AI and machine learning, enabling drug developers to replace entire genes and precisely correct mutations. This approach aims to streamline the development of curative treatments for previously incurable genetic diseases, ultimately improving the lives of patients affected by such conditions.

VitalConnect

Venture Round in 2025
VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

SPR Therapeutics

Series D in 2024
SPR Therapeutics, LLC is a medical device company focused on developing and commercializing interventional pain management therapies. The company specializes in peripheral nerve stimulation (PNS) products, including its flagship Smartpatch system, which provides short-term pain relief following surgeries and for various types of pain such as neuropathic and musculoskeletal pain. Smartpatch is designed for minimally invasive use, allowing for up to 30 days of electrical stimulation to alleviate pain. Additionally, the company offers the Micropulse system for long-term therapy through an implantable PNS solution. SPR Therapeutics aims to provide a non-narcotic alternative to opioids and invasive procedures, emphasizing safety, effectiveness, and affordability in pain management. Founded in 2009 and headquartered in Cleveland, Ohio, the company also has facilities in the Carolinas and Minneapolis.

Nouscom

Series C in 2023
Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

VitalConnect

Series F in 2023
VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Carrum Health

Series B in 2023
Carrum Health is an online healthcare platform designed to simplify the complexities and costs associated with healthcare for employers and their employees. By connecting progressive self-insured employers to top-quality regional healthcare providers, Carrum Health offers a comprehensive bundled payment solution. This innovative approach not only enhances the payment model but also aims to reduce healthcare costs for patients, often leading to low or zero out-of-pocket expenses. The platform focuses on improving the value of health benefits, ensuring a more efficient delivery of care for both employers and their members.

Vedanta Biosciences

Series E in 2023
Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Bristol Hospice

Venture Round in 2023
Bristol Hospice, established in 2006, specializes in delivering hospice and palliative care services to patients, families, and communities. The organization focuses on promoting quality and comprehensive care tailored to the needs of those it serves. Its offerings include nursing, physician services, home health aides, counseling, spiritual support, therapy, dietary assistance, and bereavement services. Additionally, Bristol Hospice provides durable medical equipment and supplies, ensuring that customers receive support for their physical, psychosocial, and spiritual needs. Through its strategic planning, the company aims to enhance the quality of life for individuals facing serious illnesses.

Carrick Therapeutics

Series C in 2022
Carrick Therapeutics, Ltd., established in 2015 and headquartered in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets molecular pathways associated with aggressive and resistant forms of cancer, employing advanced mechanisms to improve treatment outcomes. By enabling the detection of predictive biomarkers, Carrick Therapeutics facilitates the initiation of targeted therapies at early stages, ultimately striving to enhance the lives of cancer patients.

Syapse

Venture Round in 2022
Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Dren Bio

Series B in 2022
Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Iris Telehealth

Series B in 2022
Iris Telehealth is a prominent provider of telepsychiatry services in the United States, catering to community mental health centers, community health centers, hospitals, and health systems. The company specializes in connecting these facilities with qualified mental health professionals through secure videoconferencing technology. This approach allows patients to receive essential mental health care without the need for travel, thereby enhancing access to services. By facilitating remote consultations, Iris Telehealth aims to improve patient outcomes and support clinicians in delivering high-quality care, while also generating financial benefits for healthcare providers.

IntelyCare

Series C in 2022
IntelyCare, Inc. is a healthcare staffing company based in Quincy, Massachusetts, founded in 2014. It provides an on-demand staffing platform that connects nursing professionals with post-acute healthcare facilities, enabling them to optimize staffing levels and manage workforce demands effectively. The platform allows nurses and nursing assistants to create their own schedules and select shifts that suit them, fostering a flexible work environment. Utilizing advanced data science and artificial intelligence, IntelyCare automates scheduling and improves the efficiency of filling nursing shifts, achieving rates three times the industry average. The company serves a variety of clients, including home care agencies, assisted living facilities, long-term care establishments, and rehabilitation hospitals, ultimately aiming to reduce burnout among nursing staff and enhance overall productivity. IntelyCare operates as a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC.

Gravie

Series E in 2022
Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

Gravie

Series E in 2022
Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

Omada

Series E in 2022
Omada Health, Inc. is a digital healthcare company that specializes in developing online programs aimed at managing chronic conditions. Founded in 2011 and headquartered in San Francisco, California, with an additional office in Atlanta, Georgia, Omada focuses on preventing conditions such as prediabetes, diabetes, hypertension, and heart disease. The company provides personalized digital health programs that cater to the unique needs of individuals, utilizing professional health coaching, connected health devices, and real-time data to facilitate meaningful health improvements. Omada is recognized as the largest provider of the National Diabetes Prevention Program, empowering individuals to engage actively in their health and achieve sustainable lifestyle changes. The platform also addresses behavioral health issues, including anxiety and depression, further supporting individuals in their overall wellness journey.

Endeavor BioMedicines

Series B in 2022
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Verana Health

Series E in 2022
Verana Health, Inc. is a digital health company based in San Francisco, California, that specializes in transforming healthcare data into actionable insights. Founded in 2008 and formerly known as Digisight Technologies, the company connects healthcare providers with patients through innovative solutions. Its flagship product, SightBook, is a mobile application that enables users to test their vision and share results with their physicians in real-time, facilitating timely appointments and treatments. Verana Health manages data from over 20,000 healthcare providers and 70 electronic health record systems, leveraging its AI-enhanced platform, VeraQ™, to create a robust healthcare data ecosystem. By utilizing advanced analytics on curated datasets, Verana Health supports life sciences partners in improving clinical research and enhancing patient care outcomes.

HotSpot Therapeutics

Series C in 2021
HotSpot Therapeutics is a biotechnology startup based in Boston, Massachusetts, established in 2017. The company specializes in the development of allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and utilizing data science, HotSpot Therapeutics employs a multidisciplinary approach to drug discovery. This approach aims to enhance the effectiveness of treatments and improve patient outcomes across a range of conditions.

Click Therapeutics

Series B in 2021
Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

SPR Therapeutics

Series D in 2021
SPR Therapeutics, LLC is a medical device company focused on developing and commercializing interventional pain management therapies. The company specializes in peripheral nerve stimulation (PNS) products, including its flagship Smartpatch system, which provides short-term pain relief following surgeries and for various types of pain such as neuropathic and musculoskeletal pain. Smartpatch is designed for minimally invasive use, allowing for up to 30 days of electrical stimulation to alleviate pain. Additionally, the company offers the Micropulse system for long-term therapy through an implantable PNS solution. SPR Therapeutics aims to provide a non-narcotic alternative to opioids and invasive procedures, emphasizing safety, effectiveness, and affordability in pain management. Founded in 2009 and headquartered in Cleveland, Ohio, the company also has facilities in the Carolinas and Minneapolis.

Honor

Series E in 2021
Honor is a leading senior care network and technology platform that focuses on enhancing the quality of life for older adults and their families. Founded in 2014 by Cameron Ring, Monica Lo, Sandy Jen, and Seth Sternberg in San Francisco, California, Honor has established itself as a pioneer in the home care industry. The company offers expert in-home care services for seniors, leveraging an integrated system of third-party care providers. By combining scalable workforce management with personalized care, Honor enables older adults to live safely and comfortably in their own homes. In 2021, Honor expanded its reach by acquiring Home Instead, enhancing its capabilities through a global network and a relationship-based care model. This strategic move positions Honor to address the evolving needs of aging adults and professional caregivers worldwide.

US Fertility

Private Equity Round in 2021
US Fertility is a physician-owned and physician-led practice management firm specializing in the fertility sector across the United States. The company provides a comprehensive suite of business support services to top-tier fertility programs, focusing on enhancing operational efficiency and patient care. By leveraging advanced technology platforms, US Fertility effectively manages clinical and business information systems, as well as other essential functions such as finance, legal, and lab operations. Their commitment to innovation and best practices aims to improve treatment outcomes and the overall patient experience. With a strong emphasis on collaboration, US Fertility supports both domestic and international fertility practices, ensuring they can deliver exceptional care to their patients.

Genome Medical

Series C in 2021
Genome Medical, Inc. is a genomic medicine delivery company based in South San Francisco, California, established in 2016. It operates a technology platform known as Genome Care Delivery, which connects individuals and healthcare providers with genetic specialists to facilitate virtual genetic consultations. The company focuses on various areas of clinical care, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacogenomics. By providing expert genetic assessments and personalized clinical action plans, Genome Medical helps patients understand their genetic risks and make informed treatment decisions. Additionally, the company supports healthcare providers in navigating the growing field of genetics, enhancing disease diagnosis, and improving patient care while aiming to reduce overall healthcare costs.

Singular Genomics

Convertible Note in 2021
Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Gravie

Series D in 2021
Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

Gravie

Series D in 2021
Gravie, Inc. is a health insurance platform based in Minneapolis, Minnesota, that provides health insurance plans for individuals, families, and employers. Established in 2013, Gravie enables users to compare insurance options available through government-run marketplaces as well as directly from insurance companies. The company specializes in designing tailored benefits plans for employees, managing payments, and offering year-round support. Its services include Gravie Care, which allows individuals to shop for their benefits, and it utilizes a mobile application and website for ease of access. Gravie's innovative approach includes a defined contribution model, allowing employers to set fixed annual budgets for health benefits while providing tools for effective cost management. The platform also facilitates a better understanding of healthcare expenses through detailed price comparisons and information on co-pays, co-insurance, and applicable tax credits.

Nuvolo

Series C in 2021
Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform designed to support the lifecycle management of assets in various sectors, including healthcare, manufacturing, and facilities management. Founded in 2013 and headquartered in Paramus, New Jersey, Nuvolo innovates on the ServiceNow platform to provide a user-friendly experience for mobile and online users. The company’s solutions encompass implementation, support, tracking, reporting, and analytics, aimed at optimizing operational efficiency and improving asset management. Nuvolo also emphasizes security, workflow automation, and accurate inventory data, making it a comprehensive choice for businesses looking to enhance their asset management capabilities. With additional offices in London, Sofia, and Pune, Nuvolo maintains a global presence through strategic partnerships with firms such as KPMG and Unisys.

SetPoint Medical

Venture Round in 2021
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

SomaLogic

Series A in 2020
SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Included Health

Series E in 2020
Included Health is a healthcare company that provides a blend of virtual care, navigation, and community-based healthcare services to enhance the member experience. It combines advanced technology and a compassionate approach to deliver personalized care guidance and advocacy, ensuring that individuals receive the right care at the right time. The company's offerings include access to both virtual and in-person services for a range of healthcare needs, including urgent and primary care, behavioral health, and specialty care. By focusing on a member-centric model, Included Health aims to raise the standard of healthcare for everyone, making it simpler and more effective for individuals to navigate their health journey.

NeuroPace

Private Equity Round in 2020
NeuroPace, Inc. is a medical device company based in Mountain View, California, that specializes in developing and manufacturing implantable devices for treating neurological disorders, particularly epilepsy. The company's primary product is the Responsive Neurostimulator (RNS) System, designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers targeted electrical pulses to specific seizure onset areas. The RNS System comprises both implantable components, such as depth leads and cortical strip leads, and external products, including a programmer that facilitates communication with the implanted device. Founded in 1997, NeuroPace aims to transform the lives of individuals suffering from epilepsy by significantly reducing or eliminating seizures through its innovative technology. The company primarily generates revenue from sales of the RNS System to hospitals and medical facilities that perform the implantation procedures.

MISSION Therapeutics

Venture Round in 2020
MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Evidation Health

Series D in 2020
Evidation Health, Inc. specializes in developing digital tools and technologies for healthcare data analytics. The company connects digital health firms with healthcare providers and payers through its advanced platform, which transforms everyday behavior data from various sources, including sensors and devices, into actionable insights regarding health and disease. Its products include a Data Platform that analyzes this high-frequency behavior data and a technology-enabled service called Studies, which facilitates real-world research to support clinical and commercial efforts. By focusing on the interplay between everyday behaviors and health outcomes, Evidation aims to empower individuals and healthcare companies to improve health management outside traditional clinical settings. Founded in 2012 and headquartered in San Mateo, California, the company also operates additional offices in San Francisco and Santa Barbara.

Genome Medical

Series B in 2020
Genome Medical, Inc. is a genomic medicine delivery company based in South San Francisco, California, established in 2016. It operates a technology platform known as Genome Care Delivery, which connects individuals and healthcare providers with genetic specialists to facilitate virtual genetic consultations. The company focuses on various areas of clinical care, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacogenomics. By providing expert genetic assessments and personalized clinical action plans, Genome Medical helps patients understand their genetic risks and make informed treatment decisions. Additionally, the company supports healthcare providers in navigating the growing field of genetics, enhancing disease diagnosis, and improving patient care while aiming to reduce overall healthcare costs.

Arterys

Series C in 2020
Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.

Syapse

Series F in 2020
Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

IntelyCare

Series B in 2020
IntelyCare, Inc. is a healthcare staffing company based in Quincy, Massachusetts, founded in 2014. It provides an on-demand staffing platform that connects nursing professionals with post-acute healthcare facilities, enabling them to optimize staffing levels and manage workforce demands effectively. The platform allows nurses and nursing assistants to create their own schedules and select shifts that suit them, fostering a flexible work environment. Utilizing advanced data science and artificial intelligence, IntelyCare automates scheduling and improves the efficiency of filling nursing shifts, achieving rates three times the industry average. The company serves a variety of clients, including home care agencies, assisted living facilities, long-term care establishments, and rehabilitation hospitals, ultimately aiming to reduce burnout among nursing staff and enhance overall productivity. IntelyCare operates as a subsidiary of Leerink Revelation Healthcare Fund II GP, LLC.

Arcadia Solutions

Venture Round in 2020
Arcadia Solutions, LLC is a healthcare technology company based in Burlington, Massachusetts, specializing in electronic health record (EHR) data aggregation and analytics. Founded in 2002, Arcadia provides a suite of services and proprietary software aimed at large healthcare providers, payors, accountable care organizations, and health information exchanges. The company offers various IT services, including EHR implementation and optimization, performance management, and information security solutions. Additionally, Arcadia develops customizable tools for planning and maintaining health IT infrastructures, which include monitoring services to evaluate key performance indicators and manage technology lifecycle needs. By integrating diverse healthcare data into a unified platform, Arcadia enables organizations to derive actionable insights that enhance care, support research, and drive strategic growth while ensuring financial success.

Singular Genomics

Venture Round in 2019
Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Providence Medical Technology

Venture Round in 2018
Providence Medical Technology is a medical device company dedicated to developing innovative solutions for cervical spine conditions in the United States and internationally. The company specializes in the design of surgical instrumentation and implants that address cervical degenerative disc disease through a unique approach to indirect decompression and fusion. Its primary offerings include the DTRAX Spinal System, which consists of single-use disposable instruments for accessing the spine via posterior incisions, and the DTRAX Cervical Cage, designed to treat cervical radiculopathy by facilitating indirect decompression and fusion. Additionally, the company provides the DTRAX Graft, a structural allograft for posterior fusion support, and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.

Headspace

Series B in 2017
Headspace is a company dedicated to enhancing mental healthcare through its digital platform, which focuses on meditation, mindfulness, and overall mental well-being. The Headspace app features a diverse array of guided meditations led by experts, including its co-founder Andy Puddicombe, aimed at helping users reduce stress, improve focus, and cultivate mindfulness. It also offers specialized tools for sleep, such as "Sleepcasts," soundscapes, and guided sleep meditations, to aid users in achieving better rest. In addition to these features, Headspace provides mindfulness programs that address various aspects of daily life, including work, relationships, and health, while also focusing on managing mental health challenges like anxiety and depression. Furthermore, the company collaborates with organizations through corporate wellness programs, supplying resources designed to enhance employee productivity and well-being.

Vertos Medical

Venture Round in 2017
Vertos Medical Inc. is a medical device company specializing in minimally invasive treatments for lumbar spinal stenosis (LSS). Founded in 2005 and headquartered in Aliso Viejo, California, the company has developed the mild device, which provides an outpatient, fluoroscopically guided treatment for LSS without the need for implants. This innovative approach allows physicians to perform lumbar decompression procedures under local anesthesia, helping to restore space in the spinal canal, alleviate pressure on nerves, and enhance patient mobility. Vertos Medical's commitment to advancing spinal care is reflected in its focus on delivering effective solutions for common spinal diseases.

Prolacta Bioscience

Venture Round in 2016
Prolacta Bioscience Inc. is a life science company dedicated to improving the health of premature and critically ill infants in neonatal intensive care units (NICUs) through the development of standardized human milk-based nutritional products. Founded in 1999 and headquartered in Duarte, California, Prolacta specializes in creating unique formulations exclusively made from human milk, including human milk fortifiers, caloric fortifiers, and ready-to-feed formulas. Notably, it is the only company that offers a human milk fortifier composed entirely of 100% human milk, known as Prolact+ H2MF. The company operates a pharmaceutical-grade processing facility that employs patented methods to ensure the safety and quality of its products. Prolacta Bioscience is committed to advancing the science of human milk and making a significant impact on the lives of vulnerable infants through innovative research and specialized nutritional solutions.

ClearCorrect

Private Equity Round in 2016
ClearCorrect, LLC, founded in 2006 and based in Round Rock, Texas, specializes in manufacturing clear dental aligners designed to straighten teeth without the use of traditional metal braces. Operating as a subsidiary of Straumann Holding AG since 2017, the company provides a series of custom, removable aligners that are prescribed and tailored by dental professionals. Each aligner is engineered to gradually shift the teeth into the desired position, offering a comfortable and discreet alternative for patients seeking orthodontic treatment. ClearCorrect aims to deliver an effective solution for teeth alignment while ensuring affordability and ease of use for both patients and practitioners.

Cerapedics

Series D in 2016
Cerapedics, Inc. is an orthobiologics company based in Westminster, Colorado, specializing in the development and commercialization of its proprietary small peptide technology platform, specifically the biomimetic peptide molecule known as P-15. The company focuses on creating innovative solutions for spinal applications and orthopedic procedures. Its primary offerings include i-FACTOR, a peptide-enhanced bone graft designed to stimulate the natural bone healing process, and i-FACTOR+ MATRIX for surgical implantation. Founded in 2000, Cerapedics aims to provide safer and more predictable bone formation options compared to traditional bone growth factors, thereby enhancing the effectiveness of spinal fusion surgeries and other orthopedic treatments.

Akili Interactive

Series B in 2016
Akili Interactive is a digital medicine company focused on developing innovative cognitive treatments using technology. The company has a diverse pipeline of programs designed to address cognitive deficiencies and alleviate symptoms associated with various medical conditions. These include attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD), and several inflammatory diseases. By leveraging engaging digital platforms, Akili aims to improve patient outcomes in the fields of neurology and psychiatry through its unique therapeutic approaches.

Bluesight

Series B in 2015
Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to restore near vision for presbyopic patients while preserving distance vision. Additionally, AcuFocus develops the IC-8 IOL, a small aperture lens that facilitates a range of vision for patients with cataracts. The AcuTarget HD is another key product, serving as a diagnostic and surgical planning instrument for various vision correction procedures, including LASIK and cataract surgeries. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, addressing the needs of both physicians and patients in the vision care sector. Founded in 2001, AcuFocus continues to focus on innovative solutions for vision-related challenges.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.